Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis
Lingxiao Meng,Wanli Ma,Yuping Jiang,Xiaozhuang Li,Minglei Zhang,Rundong Yuan,Yaqiu Fu,Haohua Ma,Xiong Lu,Lu Han,Hongrui Liu,Minqi Li
DOI: https://doi.org/10.1002/adfm.202404549
IF: 19
2024-05-25
Advanced Functional Materials
Abstract:The step‐wise eldecalcitol delivery nanoparticles (ME‐ED‐71@PCA) with bone‐targeting ability, gastrointestinal protection, and good intestinal penetration properties is established to improve postmenopausal osteoporosis (PMOP). The ME‐ED‐71@PCA exerted superior therapeutic efficacy in re‐establishing osteogenic‐osteoclastic homeostasis in PMOP mice by promoting osteogenic differentiation of bone marrow mesenchymal stem cells as well as inhibiting the osteoclast differentiation, without side effects. Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance. Eldecalcitol (ED‐71), a novel drug for treating osteoporosis, still requires research to overcome high‐frequency delivery and low‐utilization. Here, a bone‐targeting and multishelled nanoparticles are developed for step‐wise release of ED‐71. The nanoparticles are achieved by using the chitosan/alginate outer layer as protective barrier against gastric acid, pectin middle layer as adhesive agent that improved intestinal penetration, and ethylene diamine tetraacetic acid‐grafted mesoporous silica nanomaterials core as bone‐targeting nanocarriers. After oral administration, the ED‐71‐loaded nanoparticles (ME‐ED‐71@PCA) promotes osteogenic differentiation of bone marrow mesenchymal stem cells by reducing intracellular oxidative stress, and inhibits the osteoclast differentiation. ME‐ED‐71@PCA improves bone mass in ovariectomized‐mice by promoting osteogenesis and inhibiting osteoclastogenesis, and the efficacy is more pronounced than ED‐71 alone. ME‐ED‐71@PCA exhibits satisfactory therapeutic performance due to its step‐wise drug release and bone‐targeting compared to ED‐71 administration, providing a new approach to re‐establish bone metabolic homeostasis in PMOP.
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology